Ptc Therapeutics (PTCT) Free Cash Flow (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Free Cash Flow of $126.9 million for Q2 2026, up 313.03% year-over-year from $30.7 million in Q2 2025, and up 310.7% quarter-over-quarter from -$60.2 million in Q1 2026.
Powered by 
Analysis
Ptc Therapeutics (PTCT) Free Cash Flow (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Free Cash Flow history runs 15 years deep, the most recent figure standing at $126.9 million for Q2 2026.
- In Q2 2026, Free Cash Flow rose 313.03% year-over-year to $126.9 million; the TTM figure through Jun 2026 stood at -$39.8 million (down 105.7% YoY), while the FY2025 annual figure was $702.3 million, up 715.06% from the prior year.
- Free Cash Flow for Q2 2026 stood at $126.9 million, up from -$60.2 million in the prior quarter.
- The five-year high for Free Cash Flow was $868.4 million in Q1 2025, with the low at -$174.6 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$51.5 million (2022), against an average of $4.4 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 271.31% in 2024, then jumped 1319.55% in 2025.
- Ptc Therapeutics' Free Cash Flow stood at -$174.6 million in 2022, then soared by 39.37% to -$105.9 million in 2023, then jumped by 68.1% to -$33.8 million in 2024, then retreated by 8.52% to -$36.6 million in 2025, then surged by 446.33% to $126.9 million in 2026.
- Business Quant data shows PTCT's Free Cash Flow at $126.9 million in Q2 2026, -$60.2 million in Q1 2026, and -$36.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ptc Therapeutics | 5.76 Bn | 3.54 Bn | 340.60 Mn | 126.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 126.92 Mn |
| Mar 31, 2026 | -60.24 Mn |
| Dec 31, 2025 | -36.65 Mn |
| Sep 30, 2025 | -69.82 Mn |
| Jun 30, 2025 | -59.58 Mn |
| Mar 31, 2025 | 868.38 Mn |
| Dec 31, 2024 | -33.77 Mn |
| Sep 30, 2024 | -77.51 Mn |
| Jun 30, 2024 | -64.08 Mn |
| Mar 31, 2024 | 61.17 Mn |
| Dec 31, 2023 | -105.85 Mn |
| Sep 30, 2023 | -20.88 Mn |
| Jun 30, 2023 | -20.37 Mn |
| Mar 31, 2023 | -39.76 Mn |
| Dec 31, 2022 | -174.59 Mn |
| Sep 30, 2022 | -43.43 Mn |
| Jun 30, 2022 | -63.94 Mn |
| Mar 31, 2022 | -106.72 Mn |
| Dec 31, 2021 | -77.57 Mn |
| Sep 30, 2021 | -57.03 Mn |